Varicose Veins Treatment Market Report 2025

This Varicose Veins Treatment market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The varicose veins treatment market size has grown strongly in recent years. It will grow from $1.99 billion in 2024 to $2.12 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth during the historical period can be attributed to an increase in sedentary lifestyles, a rise in outpatient treatments, growing cosmetic concerns related to varicose veins, a greater focus on preventive treatments for varicose veins, and a higher adoption of laser technologies.

The varicose veins treatment market size is expected to see strong growth in the next few years. It will grow to $2.71 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The anticipated growth in the forecast period is driven by a rising preference for minimally invasive surgeries, increasing obesity rates, the expansion of healthcare infrastructure, growing disposable incomes, and greater government spending on healthcare. Key trends in the forecast period include technological advancements, the integration of artificial intelligence, the use of 3D imaging, advanced compression therapy, and the development of combination therapies.

The growing demand for minimally invasive procedures is expected to drive the expansion of the varicose veins treatment market. Minimally invasive procedures involve the use of small incisions and specialized instruments to perform surgeries with less tissue damage, leading to less pain, quicker recovery, and minimal scarring compared to traditional open surgery. The demand for these procedures is fueled by factors such as reduced recovery times, better patient outcomes, and the aging population, which together contribute to improved patient safety, satisfaction, and healthcare efficiency. Minimally invasive treatments for varicose veins, such as endovenous laser therapy (EVLT) or sclerotherapy, offer effective solutions with minimal discomfort, faster recovery, and fewer complications. For example, The Aesthetic Society, a US-based organization, reported in August 2023 that Americans spent over $11.8 billion on aesthetic procedures in 2022, a 2% increase from the previous year. This rising preference for minimally invasive procedures is driving the growth of the varicose veins treatment market.

Companies in the varicose veins treatment market are concentrating on developing innovative solutions, such as anesthesia-free treatments, to improve patient outcomes, simplify treatment monitoring, enhance access to care, and offer personalized therapeutic approaches. Anesthesia-free treatment involves conducting medical procedures without anesthesia, ensuring safer operations, quicker recovery, and better patient comfort. For instance, in April 2024, VVT MEDICAL Ltd., an Israel-based medical device company, received approval from South Korea's Ministry of Food and Drug Safety for its ScleroSafe platform, an advanced solution for minimally invasive varicose vein treatment. This platform uses a nonthermal, nontumescent (NT-NT) method, eliminating the need for heat or tumescent anesthesia, thus providing a painless, anesthesia-free procedure. Intended for both medical and aesthetic uses, the platform focuses on patient comfort and effectiveness. It has also received several regulatory approvals, including CE Mark certification and FDA 510(k) clearance, while adhering to Good Manufacturing Practices (GMP), making ScleroSafe a groundbreaking innovation in varicose vein management.

In January 2024, VVT MEDICAL Ltd. teamed up with Methapharm Inc., a Canadian pharmaceutical company specializing in varicose vein treatment, to introduce a dual syringe technique for varicose vein treatment. This partnership enables VVT Medical to strengthen its position in the U.S. market by leveraging Methapharm’s expertise in promoting and distributing the ScleroSafe platform.

Major players in the varicose veins treatment market are Medtronic PLC, Becton Dickinson and Company, Boston Scientific Corporation, BTG Limited, Acibadem International Group, Froedtert Health Incorporated, Merit Medical Systems Incorporated, uvahealth, AngioDynamics Incorporated, Medi USA Limited Partnership, Dornier MedTech GmbH, Sciton Incorporated, Invera Medical Limited, Biolitec AG, Alma Lasers Limited, Won Tech Company Limited, F Care Systems S.A., Eufoton S.R.L., Vascular Solutions Incorporated, Theraclion S.A., uGlow Med Spa, and Varicose Veins India.

North America was the largest region in the varicose veins treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in varicose veins treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the varicose veins treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Varicose vein treatment involves medical procedures and interventions aimed at relieving symptoms, improving blood circulation, and preventing complications associated with swollen, twisted veins, primarily in the legs. It also addresses cosmetic concerns by improving the appearance of the affected veins while minimizing the risk of issues such as pain, ulcers, or blood clots.

The primary products used in varicose vein treatment include ablation devices, radiofrequency ablation devices, and laser ablation devices. Ablation devices are medical tools that remove or destroy abnormal tissue, such as tumors or varicose veins, through techniques such as heat, cold, or electrical energy. Common procedures include injection sclerotherapy, endovenous ablation, and surgical ligation or stripping. These treatments are typically provided by hospitals, specialized clinics, ambulatory surgical centers, and other healthcare providers.

The varicose veins treatment market research report is one of a series of new reports that provides varicose veins treatment market statistics, including varicose veins treatment industry global market size, regional shares, competitors with a varicose veins treatment market share, detailed varicose veins treatment market segments, market trends and opportunities, and any further data you may need to thrive in the varicose veins treatment industry. This varicose veins treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The varicose veins treatment market consists of revenues earned by entities providing services such as diagnostic services, minimally invasive treatments, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The varicose veins treatment market also includes sales of laser treatment devices, sclerotherapy agents, and radiofrequency ablation devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.